Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in Shanghai, China, focusing on the discovery, development, and commercialization of innovative drugs. The company operates in various therapeutic areas, including oncology, metabolic disorders, autoimmune diseases, and neurologic conditions. Junshi's notable products include JS001, a recombinant humanized anti-PD-1 monoclonal antibody marketed as TUOYIR for several cancers, and UBP1211, a biosimilar of Humira currently in Phase I clinical trials for rheumatoid arthritis and related conditions. Additionally, the company is advancing other drug candidates, such as JS002, a monoclonal antibody for hyperlipidemia, and several others in early-phase trials targeting various diseases. Junshi has established collaborations with leading pharmaceutical companies, including Eli Lilly and Merck, to develop therapeutic antibodies and explore new treatment combinations. Founded in 2012, Shanghai Junshi Biosciences is committed to addressing unmet medical needs through its extensive research and development initiatives.
Ruotuo Bio is a biopharmaceutical company that specializes in the development of drug research for tumors and autoimmune diseases.
Immupeutics Medicine
Seed Round in 2023
Immupeutics Medical Technology Co., Ltd. is a biomedical research company focused on the development of tumor immunotherapy. The firm specializes in creating immune cell therapy drugs aimed at treating various types of tumors and is committed to advancing companion diagnostic technology and immunological multi-omics technology. Through its research and development efforts, Immupeutics seeks to deliver innovative immune cell therapies and integrated treatment methods that enhance patient outcomes in cancer care.
GRIT Biotechnology
Series A in 2021
GRIT Biotechnology is a research and development company based in Shanghai, China, focusing on tumor infiltration lymphocytes (TIL) immunotherapy for the treatment of solid tumors. Founded in 2019, the company is dedicated to advancing the field of immunotherapy with the aim of enhancing the effectiveness of tumor treatments. By leveraging innovative approaches in TIL technology, GRIT Biotechnology seeks to provide new therapeutic options for patients battling solid tumors.
Immunophage Biotech
Series A in 2021
Immunophage Biotech is a Chinese high-tech pharmaceutic company which was established in 2016. The R&D center of the company is located in the Pujiang High-Tech Park, Shanghai, China. They are developing first-in-class immune-regulating medicines against cancer, autoimmune diseases and neurodegenerative disorders.
Zhishan Weixin Biotechnology
Series A in 2021
Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.
Coherus Biosciences
Post in 2021
Coherus Biosciences is a biopharmaceutical company that specializes in the development, manufacture, and commercialization of biologic therapeutics, with a strong emphasis on oncology and inflammatory diseases. The company is actively engaged in research and development, focusing on process science, analytical characterization, and protein production. Coherus's portfolio includes FDA-approved products such as UDENYCA, a biosimilar of Neulasta, and it plans to launch YUSIMRY, a biosimilar of Humira, in the United States. Additionally, the company is advancing a pipeline of biosimilar candidates across areas such as immunology and ophthalmology, as well as anti-tumor necrosis factor treatments. With a commitment to building an immuno-oncology franchise, Coherus aims to leverage its diversified portfolio to generate revenue and enhance patient access to biologic therapies.
IMPACT Therapeutics
Series C in 2020
IMPACT Therapeutics, Inc. is a biotechnology company based in Shanghai, China, focused on discovering, developing, and commercializing innovative therapeutics for cancer and other life-threatening diseases. Founded in 2009, the company is dedicated to creating targeted anti-cancer treatments that leverage the concept of synthetic lethality. Its research and development efforts include a variety of novel drug projects, such as PARP inhibitors, Wee1 inhibitors, and agents targeting the Hedgehog pathway, among other DNA damage response (DDR) agents. Through its commitment to advancing targeted therapies, IMPACT Therapeutics aims to provide patients with new, effective treatment options for challenging medical conditions.
Stemirna
Series A in 2020
Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.